Myasthenic Crisis

Myasthenic crisis is a complication of myasthenia gravis characterized by worsening of muscle weakness, resulting in respiratory failure that requires intubation and mechanical ventilation. Advances in critical care have improved the mortality rate associated with myasthenic crisis. This article reviews the epidemiology of myasthenic crisis and discusses patient evaluation. Therapeutic options including mechanical ventilation and pharmacological and surgical treatments are also discussed.

[1]  A. Alshekhlee,et al.  Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals , 2009, Neurology.

[2]  M. Meriggioli.  MYASTHENIA GRAVIS: IMMUNOPATHOGENESIS, DIAGNOSIS, AND MANAGEMENT , 2009 .

[3]  R. Gold,et al.  Current and future standards in treatment of myasthenia gravis , 2008, Neurotherapeutics.

[4]  E. Wijdicks,et al.  Predictors of extubation failure in myasthenic crisis. , 2008, Archives of neurology.

[5]  D. Shemin,et al.  Complications of therapeutic plasma exchange: A prospective study of 1,727 procedures , 2007, Journal of clinical apheresis.

[6]  B. Kim,et al.  Clinical predictors of steroid-induced exacerbation in myasthenia gravis , 2006, Journal of Clinical Neuroscience.

[7]  D. Rajasekaran,et al.  Drug related crisis in myasthenia gravis. , 2006, The Journal of the Association of Physicians of India.

[8]  A. Vincent,et al.  Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis , 2005, Current opinion in neurology.

[9]  A. Qureshi,et al.  An update on myasthenic crisis , 2005, Current treatment options in neurology.

[10]  A. Moayyeri,et al.  Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17-year experience , 2004, BMC neurology.

[11]  John C. Keesey,et al.  Clinical evaluation and management of myasthenia gravis , 2004, Muscle & nerve.

[12]  V. Juel.  Myasthenia gravis: management of myasthenic crisis and perioperative care. , 2004, Seminars in neurology.

[13]  A. Watanabe,et al.  Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. , 2004, The Journal of thoracic and cardiovascular surgery.

[14]  W. Beuche,et al.  Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin , 2003, Pain.

[15]  E. Wijdicks,et al.  Warning Signs of Imminent Respiratory Failure in Neurological Patients , 2003, Seminars in neurology.

[16]  J. Ulatowski,et al.  Ventilatory care in myasthenia gravis crisis: Assessing the baseline adverse event rate* , 2002, Critical care medicine.

[17]  E. Wijdicks,et al.  BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation , 2002, Neurology.

[18]  D. Sanders,et al.  On the Concept of Myasthenic Crisis , 2002, Journal of clinical neuromuscular disease.

[19]  J. Lewis,et al.  Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders , 2001, Neurology.

[20]  E. Svastics,et al.  Decade-long experience with surgical therapy of myasthenia gravis: early complications of 324 transsternal thymectomies. , 2001, The Annals of thoracic surgery.

[21]  D. Younger,et al.  Therapy in neuromuscular disease. , 2001, Neurologic clinics.

[22]  G. Gronseth,et al.  Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) , 2000, Neurology.

[23]  J. Ulatowski,et al.  Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis , 1999, Neurology.

[24]  J. C. Cobeta,et al.  Influence of calcium antagonist drugs in myasthenia gravis in the elderly , 1998, Journal of clinical pharmacy and therapeutics.

[25]  S. Mayer,et al.  Therapy of myasthenic crisis. , 1998, Critical care medicine.

[26]  D. Miller,et al.  The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit , 1998, European journal of neurology.

[27]  S. Chevret,et al.  Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravis , 1997 .

[28]  T. Konishi.  [A case of myasthenia gravis which developed myasthenic crisis after alpha-interferon therapy for chronic hepatitis C]. , 1996, Rinsho shinkeigaku = Clinical neurology.

[29]  T. Bertorini,et al.  Complications of intravenous gammaglobulin in neuromuscular and other diseases , 1996, Muscle & nerve.

[30]  R. Wise,et al.  Myasthenia gravis and upper airway obstruction. , 1996, Chest.

[31]  J. Chevrolet,et al.  The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis , 1995, Intensive Care Medicine.

[32]  D. Gambling.  Anaesthesia and myasthenia gravis , 1992, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[33]  M. Swash,et al.  Adverse effect of verapamil in myasthenia gravis , 1992, Muscle & nerve.

[34]  R. Kakigi,et al.  Exacerbation of myasthenia gravis shortly after administration of methimazole for hyperthyroidism. , 1991, Japanese journal of medicine.

[35]  L. Ginsberg,et al.  Ciprofloxacin and myasthenia gravis. , 1990, BMJ.

[36]  I. Wirguin,et al.  Aggravation of human and experimental myasthenia gravis by contrast media , 1990, Neurology.

[37]  E. May,et al.  Aggravation of myasthenia gravis by erythromycin , 1990, Annals of neurology.

[38]  D. A. Krendel,et al.  Myasthenia gravis presenting as weakness after magnesium administration , 1990, Muscle & nerve.

[39]  M. Green,et al.  Respiratory muscle function in myasthenia gravis. , 1988, The American review of respiratory disease.

[40]  O. Abramsky,et al.  Ampicillin may aggravate clinical and experimental myasthenia gravis. , 1986, Archives of neurology.

[41]  H. Coslett,et al.  Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 Patients , 1984, Annals of neurology.

[42]  R. Rodnitzky,et al.  Complications of plasma exchange in neurological patients. , 1982, Archives of neurology.

[43]  D. Younger,et al.  ASPECTS OF THE NATURAL HISTORY OF MYASTHENIA GRAVIS: CRISIS AND DEATH , 1981, Annals of the New York Academy of Sciences.

[44]  T. Torda,et al.  The nature of gentamicin-induced neuromuscular block. , 1980, British journal of anaesthesia.

[45]  J. Brumlik,et al.  Myasthenia Gravis Associated with Diphenylhydantoin Therapy For Epilepsy , 1974, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[46]  D. Drachman,et al.  Procainamide---a hazard in myasthenia gravis. , 1965, Archives of neurology.

[47]  E. Hokkanen.  Antibiotics in Myasthenia Gravis , 1964, British medical journal.

[48]  S. Weisman.  Masked myasthenia gravis. , 1949, Journal of the American Medical Association.

[49]  Pan‐Chyr Yang,et al.  The Role of Non-invasive Ventilation and Factors Predicting Extubation Outcome in Myasthenic Crisis , 2009, Neurocritical care.

[50]  E. Wijdicks,et al.  Noninvasive ventilation in myasthenic crisis. , 2008, Archives of neurology.

[51]  A. Rabinstein,et al.  Risk of extubation failure in patients with myasthenic crisis , 2005, Neurocritical care.

[52]  L. Rowland,et al.  Myasthenic crisis , 2004, Current treatment options in neurology.

[53]  D. Kiprov,et al.  Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. , 1993, Archives of neurology.

[54]  H. Kaeser.  Drug-induced myasthenic syndromes. , 1984, Acta neurologica Scandinavica. Supplementum.